The concept of “Dayenu” may have originated from a religious context, but its underlying principles can offer valuable secular lessons, even in healthcare. In the practice of medicine, embracing gratitude and contentment for small victories can have a significant impact on patient care. Physicians can encourage patients to adopt an attitude of gratitude for any
Health
Disrupted circadian rhythms in cognitively normal adults have been found to be associated with higher subsequent amyloid-beta levels. This relationship is particularly strong in APOE4 carriers and remains consistent even after excluding participants with baseline Alzheimer’s pathology. The findings from a recent study shed light on the potential impact of fragmented 24-hour activity rhythms on
The recent approval by the FDA for the use of efgartigimod alfa and hyaluronidase in the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) has been described as a groundbreaking day for CIDP treatment. According to Jeffrey Allen, MD, of the University of Minnesota, who served as a principal investigator for the drug’s pivotal
The preliminary report of a drug sample containing various substances, including medetomidine, highlighted the alarming trend of emerging drugs in the illicit opioid supply. Medetomidine, a drug with similarities to xylazine, has been causing unexpected overdoses that are challenging to manage. With its potent effects and long-lasting impact, medetomidine has led to hospitalizations and overdoses
The LENS trial, conducted by David Preiss, MBChB, PhD, revealed that fenofibrate has the potential to reduce the progression of early diabetic retinopathy and maculopathy among diabetes patients. Over a span of 4 years, the fibrate showed a relative 27% decrease in disease progression when compared to a placebo. This groundbreaking information was presented at
The recent findings surrounding osimertinib (Tagrisso) in patients with EGFR-mutated non-small cell lung cancer (NSCLC) from both the LAURA and ADAURA trials have sparked excitement in the medical community. Dr. Roy Herbst, from Yale Cancer Center in New Haven, Connecticut, discusses the improvements in progression-free survival (PFS) in stage III patients and the potential of
An analysis of medical records involving over 88,000 systemic lupus erythematosus (SLE) patients has revealed promising results for those taking metformin. The research conducted by Yurilu A. Gonzalez Moret, MD, and colleagues at Thomas Jefferson University suggests that individuals with SLE who are on metformin are at a lower risk of developing lupus nephritis, chronic
Patients diagnosed with rheumatoid arthritis (RA) often face a heightened risk of cardiovascular events and mortality. Traditional risk factors such as smoking, obesity, and hypertension do not fully account for the increased cardiovascular risk observed in RA patients. This has led researchers to explore additional biomarkers that could help predict major adverse cardiovascular events (MACE)
A recent study has shed light on the missed opportunities in treating drug overdose survivors under the Medicare program. It highlighted the challenges of managing chronic pain in this vulnerable population. Despite recommendations from experts to prioritize comprehensive treatment for overdose survivors, the reality is quite different. The study found that a significant number of
The approval of PD-1-directed immune checkpoint inhibitor pembrolizumab in combination with carboplatin and paclitaxel is a significant advancement for patients with primary advanced or recurrent endometrial cancer. The results of the KEYNOTE-868/NRG-GY018 trial showed that patients with either mismatch repair (MMR)-deficient or MMR-proficient disease benefited from this immunotherapy-chemotherapy combination. In the trial, the addition of